Last reviewed · How we verify
r-tPA
r-tPA is a recombinant tissue plasminogen activator that converts plasminogen to plasmin, breaking down fibrin clots to restore blood flow.
r-tPA is a recombinant tissue plasminogen activator that converts plasminogen to plasmin, breaking down fibrin clots to restore blood flow. Used for Acute ischemic stroke, Acute myocardial infarction, Pulmonary embolism.
At a glance
| Generic name | r-tPA |
|---|---|
| Sponsor | Thrombolex, Inc. |
| Drug class | Fibrinolytic agent / Thrombolytic |
| Target | Plasminogen |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
r-tPA is a serine protease that binds to fibrin in thrombi and catalyzes the conversion of plasminogen to plasmin, which degrades the fibrin matrix of blood clots. This fibrinolytic action dissolves thrombotic occlusions and restores perfusion in occluded vessels. It is used acutely to restore blood flow in thrombotic events such as ischemic stroke and myocardial infarction.
Approved indications
- Acute ischemic stroke
- Acute myocardial infarction
- Pulmonary embolism
Common side effects
- Bleeding (intracranial hemorrhage)
- Reperfusion arrhythmias
- Hypotension
- Allergic reactions
Key clinical trials
- Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion (EARLY_PHASE1)
- Intra-arterial Thrombolysis After Successful Thrombectomy for Acute Ischemic Stroke in the Posterior Circulation (IAT-TOP) (NA)
- Percutaneous Embolectomy, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism (PHASE3)
- Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake (PHASE4)
- EXtending the Time Window for Thrombolysis in Posterior Circulation Stroke Without Early CT Signs (PHASE3)
- Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE (PHASE4)
- Endovascular Acute Stroke Intervention Trial - the EASI Trial (NA)
- Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- r-tPA CI brief — competitive landscape report
- r-tPA updates RSS · CI watch RSS
- Thrombolex, Inc. portfolio CI